-
Sector Analysis
Progressive Pulmonary Fibrosis (PPF): Epidemiology Report and Forecast to 2035
Progressive pulmonary fibrosis (PPF) is a distinct form of progressive and fibrotic disease, occurring in interstitial lung disease (ILD) cases other than in idiopathic pulmonary fibrosis (IPF). PPF is mostly defined by clinical symptoms, lung function, and chest imaging, irrespective of the underlying condition. PPF progression is monitored through a combination of pulmonary function tests such as forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide, an assessment of symptoms, and computed tomography (CT) scans, along...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, July 2026
Why Does Bio/Pharmaceutical Outsourcing Matter? Bio/pharmaceutical outsourcing plays an important role in pharmaceutical manufacturing, with contract manufacturing organizations (CMOs) responding to changing demand, regulatory requirements, technology investment, and supply chain dynamics. This monthly report provides analysis of the latest business conditions and developments affecting the pharmaceutical outsourcing industry. It tracks outsourcing contracts, CMO mergers and acquisitions, financing, facility openings and closures, GMP inspections, technology investments, supply chain challenges, and emerging opportunities and threats. You can use this report to: Monitor...
-
Sector Analysis
Tuberous Sclerosis Complex (TSC): Market View, Current and Future Competitive Landscape
Why Does the Tuberous Sclerosis Complex Therapeutics Market Matter? Tuberous Sclerosis Complex (TSC) is a multidisciplinary disease requiring symptom-driven management across seizures, TSC-associated tumors, and organ-specific manifestations affecting the brain, kidneys, lungs, skin, and heart. In 2025, there were 198,627 diagnosed prevalent cases of TSC-associated epilepsy across the 16 countries covered in GlobalData's epidemiology forecast. Treatment includes anti-seizure medications, dietary and surgical options for refractory epilepsy, surveillance, and supportive interventions. Marketed mTOR therapies such as everolimus and topical sirolimus are...
-
Sector Analysis
Chronic Kidney Disease in Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the chronic kidney disease (CKD) market through 2035. GlobalData estimates the sales of CKD therapeutics to be approximately $4.3 billion across the 7MM in 2025. By 2035, GlobalData expects the CKD market to grow at a strong compound annual growth rate (CAGR) of 9.8%, reaching sales of $10.9 billion by the end of the forecast period. The major drivers of CKD market growth over the...
-
Sector Analysis
Major Depressive Disorder: Epidemiology Report and Forecast to 2035
Why Does Major Depressive Disorder Epidemiology Matter? Major depressive disorder (MDD), also known as clinical depression, is a complex mental health condition associated with persistent changes in mood, interest, cognition, and physical functioning. While treatment options include antidepressant medications, psychotherapy, and advanced neuromodulation, some patients experience treatment-resistant depression (TRD), creating distinct considerations for treatment development and market planning. Understanding the size, characteristics, and evolution of patient populations is essential for pharmaceutical companies and healthcare stakeholders evaluating the MDD treatment landscape....
-
Sector Analysis
Ireland in the IRP Crossfire
Ireland's decision to exclude the UK from its international reference pricing (IRP) basket from 2027 will exert mild downward pressure on achievable ex-manufacturer prices for innovative medicines, a GlobalData analysis of POLI data across 22 recently reimbursed products finds.
-
Thematic Analysis
Global M&A Deals in H1 2026 - Top Themes by Sector: Strategic Intelligence
Why Does M&A Activity Matter? Mergers and acquisitions can provide a view into the themes reshaping industries and where companies are directing capital and strategic investment. The global M&A market recorded $1.7 trillion in deal value in H1 2026, up 47% from H1 2025. This report analyzes the most notable transactions across major sectors and identifies the disruptive themes driving M&A activity. You can use this report to: Understand the scale and direction of global M&A activity Identify disruptive themes...
-
Sector Analysis
Graft versus Host Disease (GvHD): Epidemiology Report and Forecast to 2035
Graft-versus-host disease (GvHD) is a common and potentially serious complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT is used as a potential cure for hematological cancers, syndromes of bone marrow failure, and congenital disorders of the hematopoietic system (Hymes, Alousi and Cowen, 2012; Passweg et al., 2025). GvHD occurs when the donor stem cells or the graft attack healthy cells in the patient or the host (Blood Cancer United, 2024). GvHD can damage a patient’s tissues and...
-
Thematic Analysis
Pharmaceutical Drug Development Annual Review 2025
This report investigates the year 2025 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Thematic Analysis
Modality Intelligence - From Pipeline to Capital: Strategic Intelligence
Antibodies lead pipeline volume and forecast sales, and drive approvals alongside recombinants, but oligonucleotides are scaling fastest off a smaller base. Maturity and innovation stage, not pipeline size, determine where capital lands next. Capital is consolidating around modalities with proven commercial models, and the cost of entry into mAbs, ADCs, siRNA, and BsAbs is rising across M&A, licensing, and VC alike. Within mAbs and recombinants, capital is rotating out of mature mAb mega-deals and into early-stage ADC and recombinant platform...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.